BioSpace News Archive

2seventy bio to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference.

Piezo Motion, a Brain Scientific company, announces the release of rotary motors for devices or applications requiring rapid response times, high-torque, micro-radian resolution and almost zero backlash.

EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that three oral presentations will be delivered on its HIFU developments at the 21st Annual International Symposium on Therapeutic Ultrasound (ISTU), which is being held June 7-10, in Toronto and virtually.

AltruBio Inc. announced that president and chief executive officer Judy Chou, Ph.D., will present an in-person corporate overview at the 2022 BIO International Convention taking place June 13-16, 2022 in San Diego, Calif.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis, announced its support for the fifth International NASH Day, taking place on June 9, 2022.

Haemonetics Corporation has posted its full lineup of speakers planned for the Company’s Investor Day, to be hosted in Boston on Wednesday, June 29, 2022, with presentations beginning at 10:00 AM EDT.

S2 Genomics, a manufacturer of automated tissue sample preparation systems, announced at the Advances in Genome Biology and Technology 2022 general meeting the launch of the NIC+ Small Sample Cartridge for nuclei isolations from solid tissue.

Veru Inc announced that the final results from the Phase 1b/2 clinical study of sabizabulin, a novel oral cytoskeleton disruptor, in 80 men with metastatic castration resistant prostate cancer that progressed after receiving at least one androgen receptor targeting agent was presented at a poster session during the 2022 American Society of Clinical Oncology Annual Meeting which is being held June 3-7, 2022.

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, announced that senior management will present at the following upcoming investor conferences.

The Ottawa Hospital, The Ontario Institute of Cancer Research and Intensity Therapeutics, Inc. presented data from the INVINCIBLE study, a randomized, phase 2 presurgical Window-Of-Opportunity trial for Intratumoral INT230-6 comprising SHAO, VINblastine and Cisplatin that is evaluating clinical and Biological Effects in patients with early-stage operable breast cancer.